



- (51) **International Patent Classification:**
C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61P 27/02 (2006.01) *C12N 5/079* (2010.01)
- (21) **International Application Number:**
PCT/US2024/032131
- (22) **International Filing Date:**
31 May 2024 (31.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/505,333 31 May 2023 (31.05.2023) US
- (71) **Applicant:** **STOKE THERAPEUTICS, INC.** [US/US];
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
- (72) **Inventors:** **AZNAREZ, Isabel**; c/o Stoke Therapeutics,
Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730
(US). **VENKATESH, Aditya**; c/o Stoke Therapeutics,
Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730
(US). **RAVIPATY, Shobha**; c/o Stoke Therapeutics, Inc.,
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
MEENA, Meena; c/o Stoke Therapeutics, Inc., 45 Wiggins
Avenue, Bedford, Massachusetts 01730 (US). **PETERS,**


David Grant; c/o Stoke Therapeutics, Inc., 45 Wiggins Av-
enue, Bedford, Massachusetts 01730 (US).

- (74) **Agent:** **NIP, Lisa** et al.; Wilson Sonsini Goodrich & Rosati,
650 Page Mill Road, Palo Alto, California 94304 (US).

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

- (54) **Title:** OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES



- (57) **Abstract:** Alternative splicing events in genes can lead to nonproductive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

05 June 2025 (05.06.2025)